All News

Industry investment in pharma sales force and marketing channels remained “flat” in 2013 at just under €85 billion constant US dollars.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) yesterday launched what it called “a landmark paper” outlining steps towards an integrated strategy for the life sciences sector in Europe.

While at the 2014 New York BIO Conference (NYBIO), Applied Clinical Trials‘ Moe Alsumidaie spoke to Nathan Tinker, Executive Director at the New York Biotechnology Association.

Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report.

Eli Lilly and Company has announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com.

There is more collaboration than ever between payers and providers in the drive to provide high-quality.

One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”.

A European bid to impose additional limits on research involving human embryos has been defeated.

I’ve been lucky enough to get a sneak preview of Across Health’s 2014 Multichannel Barometer report.

The Obama administration received a substantial amount of good news last month.

Vietnam’s pharma market in Vietnam is set to increase by $5 billion over the next six years.

Turkey is remains a key destination for foreign investment, and the next five years should see renewed interest from pharma multinationals, says a new report by CPhI Worldwide.

Effective clinical trial management depends on accurate and unbiased performance measurement.

FDA, in partnership with other federal and international agencies, has taken action against websites that sell potentially dangerous, unapproved prescription drugs to US consumers.

While some clinical trial sponsors have been driven out of the BRIC nations.

We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program.

In today’s pharmaceutical industry, it seems there are nearly as many communication channels as there are instruments in the Philharmonic.

Pharm Exec’s Brand of the Year selections from the last few years are still alive and kicking, although some have aged more gracefully than others.

Technology offers the promise of engaging patients on a level never seen before.

In the last three decades, MNCs have contributed greatly to the transfer of knowledge to generic companies in areas such as technology,

Every day, your competitors are doing everything within their power to steal your customers.

The three leading justifications for sticker-shocking drug prices in the US.

There has been a lot of concern about the decision to give the National Institute for Health and Care Excellence (NICE) the responsibility to look at “highly specialized technologies” (HSTs, or orphan drugs to you and me).

Global price management will lead the fight-back on margins, writes Arnaud Grunwald.

The European Medicines Agency thought it might at last be back on the road to salvation when Guido Rasi swept into town in 2011 and started ordering greater transparency in the agency’s operations.

Vaccine development is on a roll, boosted by biomedical research uncovering new molecular targets for preventives and treatments.

Human behavior may be the most significant variable in the future of cancer care in two sense.

For any Brit involved in medical publishing, the British Medical Journal (BMJ) is the Holy Grail.

PharmSource recently completed an analysis of the dose CMO industry’s share of new FDA approvals.

At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,